Aimmune Therapeutics Inc.
www.aimmune.com
Latest From Aimmune Therapeutics Inc.
Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic
With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.
Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam
The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA's Shutdown Offers One Possible Winner
For most sponsors, shutdown's impact won’t be too dramatic – but for two peanut allergy companies, the stoppage had very different implications.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Immune Disorders
- Alias(es)
- Allergen Research Corp.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Aimmune Therapeutics Inc.
- Senior Management
-
Jayson Dallas, Pres. & CEO
Eric Bjerkholt, CFO
Jeffrey H Knapp, PhD, COO
Daniel C Adelman, MD, CMO
Mary Rozenman, PhD, SVP, Corp. Dev. & Strategy - Contact Info
-
Aimmune Therapeutics Inc.
Phone: (650) 614-5220
8000 Marina Blvd.
Ste. 300
Brisbane, CA 94005
USA
Advertisement
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aimmune Therapeutics Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice